Synta Pharma (SNTA) Cash Flow Statement

Click line-items for a historical chart and %

Net loss
Stock-based compensation expense	8.1M
Depreciation and amortization
Collaboration receivable
Prepaid expenses and other current assets
Other assets
Accounts payable	269.74K
Accrued contract research costs
Other accrued liabilities
Deferred collaboration revenue
Net cash used in operating activities
Purchases of marketable securities	-2.99M
Maturities of marketable securities	8.58M
Purchases of property and equipment	-1.48K
Net cash used in investing activities
Proceeds from issuance of common stock and exercise of common stock options, net of transaction costs
Proceeds from term loans
Payment of term loans
Payment of capital lease obligations
Net cash provided by financing activities
Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of period	306.25K
Cash and cash equivalents at end of period	8.39M
Cash paid for interest

Entities mentioned with SNTA

View All Entities